US$ 28.60
foxo4-dri senolytic human trial 2024 2025 Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis FOXO4-DRI part 2! Please let's
Description
Dosing: 1,000 micrograms sublingual daily [12]
Watch for warning signs
The tripeptide itself is stable, but the copper complex requires careful handling to maintain the metal-peptide association
If youd like to speak to us beforehand, feel free to call 01425 613971 our team will be happy to help